Heterozygotes are clinically asymptomatic, but a number of epidemiological studies in AT families have noted a significant increase in cancer incidence, in breast cancer particularly (Easton, 1994; Athma et al, 1996; Inskip et al, 1999; Janin et al, 1999; Olsen et al, 2000) . The relative risk was in the range 1.5-9, depending on population, age and family relation. Interestingly, cancer deaths do not appear to be significantly increased. Few of these studies have analysed carrier status and the number of observed breast cancer cases is relatively low, resulting in low statistical power.
A broad spectrum of breast cancer patients have been screened for mutations in the ATM gene: unselected series, patients with early-onset and late-onset disease, patients in cancer families, patients showing adverse reactions to radiation therapy, a cohort with frequent occurrence of bilateral disease, and Hodgkin's patients who developed breast cancer after radiation treatment. Only two of these studies found proportions of truncating mutations above the population estimate. Vorechovsky et al (1996a) screened 88 breast cancer patients in cancer families. Three index cases carried truncating mutations, but the mutations did not consistently segregate with the disease in the families. Broeks et al (2000) found seven truncating mutations in 82 breast cancer patients characterized by frequent bilateral occurrence, early ageof-onset, and long-term survival. Three of these patients carried the same intronic alteration, IVS10-6 G/T, the function of which is uncertain. Several studies did not find an excess of classical ATM mutations in breast cancer patients (Vorechovsky et al, 1996b; Appleby et al, 1997; Fitzgerald et al, 1997; Chen et al, 1998; Shayeghi et al, 1998; Bebb et al, 1999; Izatt et al, 1999; Oppitz et al, 1999) . The statistical power is generally low in these studies due to small numbers of ATM mutation carriers (Bishop and Hopper, 1997) and most studies have screened for classical truncating mutations only. There is a possibility that the mutation spectrum in breast cancer patients is different from the spectrum in AT patients. Gatti et al (1999) hypothesize that missense mutations result in breast cancer in heterozygotes, but not in classical AT in homozyogtes.
The aim of the present study was to screen a large number of Norwegian breast cancer patients for six unique ATM mutations found in Norwegian AT patients. The six mutations constituted 83% of the disease alleles in the Norwegian AT patients (Laake et al, 1998 (Laake et al, , 2000 . One single mutation constitutes 57% of the disease alleles. Three others were recurrent in the Nordic countries ( Table 1 ). The ascertainment of the AT patients was populationbased in the years 1975 -1994 , and we assume that the majority of the ATM disease-causing alleles in our population are represented by these six mutations. A simple multiplex PCR analysis was developed to screen for these mutations with a high throughput.
MATERIALS AND METHODS
The breast cancer patients belonged to three different series collected at different hospitals. The Norwegian Radium Hospital, Oslo, 295 cases (Andersen et al, 1994) ; Ullevål University Hospital, Oslo, 136 cases Hospital, Bergen, 52 cases (Aas et al, 1996) . The median age at diagnosis was 59 years, range 27-90 years. The six mutations screened for are described in Table 1 (Laake et al, 1998 (Laake et al, , 2000 . Genotyping was performed in microtitre plates by a multiplex PCR in a 25 µl reaction volume containing 50-200 ng leukocyte DNA, 1 × Perkin Elmer buffer I, 4 mM MgCl 2 , 0.15 mM of each of the dNTPs, 0.04 U AmpliTaq, 0.2 µM of each primer, except for the primers ATEX60F and ATEX60R of which 0.6 µM was used. Primer sequences are shown in Table 2 . The PCR programme was: 94˚C for 2 min; 30 cycles of 30 s at 94˚C, 45 s at 56˚C and 45 s at 72˚C; followed by 2 min at 72˚C, 1 min at 94˚C and 60 min at 65˚C to allow heteroduplex formation. The PCR products were electrophoresed in a 7.5% polyacrylamide gel (1:37.5 bis content) at 150 V for 50 min in 1 × TAE buffer. The gel was stained with ethidium bromide and photographed under UV light. All cases showing aberrantly migrating bands were sequenced.
Exact 95% confidence intervals for the mutation frequency were estimated by StatXact (binomial distribution). Power estimations were performed by normal approximation to the binomial distribution (nQuery).
RESULTS
A simple multiplex PCR was used to screen 483 breast cancer patients for presence of six ATM mutations seen in homozygous AT patients. The migration patterns of the different mutants are shown in Figure 1 . Only one breast cancer patient (ULLB-120) was found to carry an ATM mutation, the Norwegian founder mutation (3245-3247 delATC insTGAT). The patient was first diagnosed with a lobular breast carcinoma (T2, N0, M0) at the age of 44. Four years later she developed a tubular carcinoma (T1, N0, M0) in the contralateral breast. The patient was alive and disease-free at age 52. No family history of breast cancer in first-degree relatives was recorded at time of diagnosis. Her first carcinoma did not exhibit LOH at any of seven microsatellite markers within and surrounding the ATM gene (Laake et al, 1997) .
The frequency of classical ATM mutations in the patients analysed was 1/483, i.e. 0.2%; 95% CI = 0.01-1.2. According to the upper limit of this estimate of 1.2%, and the 0.5% estimated population frequency for ATM heterozygosity in the Nordic population , the present data are consistent with a maximum of 2.4-fold increased lifetime risk of breast cancer. The present study had 95% power to detect a 4.6-fold elevated lifetime risk according to the number of cases analysed, estimated by one sample two-sided chi-square test at a 5% significance level (Table 3) . Table 2 Primer sequences   EX23F2  GGC ATC TAA CAA AGG AGA GG  EX24R2  TGT AAG ACA TTC TAC TGC CAT C  EX33F  CAC AGA AAC TAA AAG CTG GGT A  EX33R  TGC CTG GCC TAC GTA TAT  EX55F  TGT TGG GTA GTT CCT TAT GT  EX55R  CAA GGG CAG TTT TAG TAA C  EX58F  ATG AAA GAA TGG CAG TAG GT  EX58R  CCT CCC AAA GCA TTA TGA  EX64F  CTC AAG GAA ACA TGA AGT GTG  EX65R  GCA GAG ATG TTC CTT AAG ACC  EX60F  TGC CCC TAT ATC TGT CAT AT  EX60 CTC AAT CTA CTA TAT GTA CAA G 
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DISCUSSION
In the epidemiological study of cancer risk in Nordic AT relatives, the highest standard incidence ratio (SIR) of breast cancer, 8.5 (95% CI = 2.7-20), was found among mothers of AT children, aged below 55. The present study had more than 95% power to detect the point estimate of 8.5, but only 38% power to detect the lower 95% confidence limit of 2.7 (Table 3) . Concerning lifetime risk of breast cancer, mothers again showed the highest SIR, 7.1 (95% CI = 2.3-17). The present study had more than 95% power to detect a 7.1-fold increased lifetime risk of breast cancer, but only 51% power to detect the lower 95% confidence limit (2.3) of the estimated SIR.
There is a possibility that ATM mutations are carried by a subgroup of breast cancer patients with distinct characteristics. Most of the epidemiological studies of AT relatives report an increased risk of breast cancer at younger ages, below 45-55 years (Inskip et al, 1999; Janin et al, 1999; Olsen et al, 2000) , contrary from Athma et al (1996) . In the present study, only 150 of the patients analysed were below the age of 55 at time of diagnosis, which may explain the low frequency of mutations seen. Among the patients analysed in the present study, about 25% of the cases were diagnosed with advanced breast cancer (stages III and IV). However, there is no evidence that breast cancer patients carrying ATM mutations are diagnosed with advanced cancer. A subgroup of patients found to carry ATM mutations is those with radiationinduced bilateral breast cancer at young age with good prognosis (Broeks et al, 2000) . However, no excess of truncating ATM mutations were found in three small cohorts of breast cancer patients showing tissue radiation side-effects (Appleby et al, 1997; Shayeghi et al, 1998; Oppitz et al, 1999) .
The studied mutations have been associated with breast cancer in AT relatives. Eight cases were identified among the Norwegian relatives . One of them had the Norwegian founder mutation and the other the deletion in exon 33 (unpublished results) . Carrier status of the other cases are still unknown. Vorechovsky et al (1996a) also found one woman with breast cancer carrying the Norwegian founder mutation. No missense mutations were screened for in the present study. There are, however, several reports on germline amino acid substitutions in breast cancer patients with frequencies ranging from 7-41% (Vorechovsky et al, 1996a (Vorechovsky et al, , 1996b Appleby et al, 1997; Larson et al, 1998; Shayeghi et al, 1998; Izatt et al, 1999) . Gatti et al (1999) mutations may both be at risk for breast cancer, but the frequency of the ATM mis/wt will be much higher in the population than the ATM trunc/wt carrier. It is not evident whether ATM acts as a tumour suppressor gene or not. None of the tumours showing LOH in the ATM region in a previous study (Laake et al, 1997) carried any of the six analysed mutations. This is in agreement with Vorechovsky et al (1996b) . Recently, Izatt et al (1999) reported loss of the wild type allele in five breast cancer patients carrying different missense substitutions in the ATM protein, suggesting that LOH coincides with ATM missense mutations in breast cancer development.
The effect of the different missense substitutions on the function of the ATM protein is unknown. Some of these substitutions most likely induce minimal changes (polymorphisms), whereas others abrogate protein function. Functional studies, extended knowledge of the ATM protein structure and function, in addition to case control studies, will elucidate whether carriers of these variants are at risk of developing breast cancer.
